help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 3, 338-340, March 2007; doi:10.1634/theoncologist.12-3-338
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hayslip, J.
Right arrow Articles by Fenning, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayslip, J.
Right arrow Articles by Fenning, R.

Lymphoma

Safe Administration of Iodine-131 Tositumomab After Repeated Infusion-Related Reactions to Rituximab

John Hayslip, Robert Fenning

Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA

Key Words. Follicular lymphoma • Antibodies • Monoclonal • Radioimmunotherapy • Adverse effects

Correspondence: John Hayslip, M.D., 96 Jonathan Lucas Street, CSB 903, PO Box 250635, Charleston, South Carolina 29425, USA. Telephone: 843-792-4271; Fax: 843-792-0644; e-mail: hayslip{at}musc.edu

Infusion-related reactions during administration of monoclonal antibody therapy are often mild and unlikely to recur with subsequent treatment. If patients experience another severe reaction upon reattempting treatment, future treatments with the same agent are typically not pursued. It is unclear whether different monoclonal antibodies that bind the same tumor cell or antigen are likely to induce similar infusion reactions. Here, we report the case of a patient with repeated severe infusion reactions with rituximab who subsequently safely received treatment with iodine-131 tositumomab and discuss the relevant literature.

Disclosure of potential conflicts of interest is found at the end of this article.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2007 by AlphaMed Press.